Nuvectis Pharma (NVCT) Net Equity Issued and Repurchased (2021 - 2026)
Nuvectis Pharma (NVCT) posted Net Equity Issued and Repurchased of $7000.0 for Q1 2026, down 96.0% sequentially from $175000.0 in Q4 2025, and down 99.45% YoY from $1.3 million in Q1 2025.
Nuvectis Pharma (NVCT) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $7000.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 99.45% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 69.5% YoY) and the FY2025 annual result came in at $15.7 million, up 30.44% from the prior year.
- Net Equity Issued and Repurchased fell to $7000.0 in Q1 2026 per NVCT's latest filing, from $175000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $13.5 million in Q3 2025 and troughed at $7000.0 in Q1 2026.
- A 4-year average of $2.7 million and a median of $1.3 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased jumped 800.0% in 2025, then sank 99.45% in 2026.
- Over 4 years, Net Equity Issued and Repurchased stood at $901000.0 in 2023, then soared by 338.73% to $4.0 million in 2024, then tumbled by 95.57% to $175000.0 in 2025, then plunged by 96.0% to $7000.0 in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $7000.0, $175000.0, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 175,000.00 |
| Dec 31, 2025 | 175,000.00 |
| Sep 30, 2025 | 13.50 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 3.95 Mn |
| Dec 31, 2024 | 3.95 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Mar 31, 2024 | 4.85 Mn |